

Dear Editor,

Thank you very much for giving us a chance to revise the manuscript. We have carefully read the reviewers' comments on the manuscript and revised the manuscript based on these comments. We also have revised the manuscript to make it conforming to the journal style.

Please find attached point-by-point responses to the reviewers' comments.

Yours sincerely,

Xiaosheng Wang, MD, PhD

School of Basic Medicine and Clinical Pharmacy

China Pharmaceutical University

E-mail: xiaosheng.wang@cpu.edu.cn

Response to Reviewer reports:

Reviewer's code: 03522824

1) The abbreviation should mention in full words for the first time e.g. PD-L1.

Response: I thank the reviewer for the comment. Following the comment, I have added full words for the abbreviations when they appeared for the first time.

2) Based on the author hypothesis, any compound with potential ACE2 inhibition action should be avoided in cancer patients or cancer patient with Covid-19 ... it should be included as a conclusion in the abstract section.

Response: I thank the reviewer for the suggestion. Following the suggestion, I have added the conclusion in the abstract section.